Equillium Inc (EQ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.21-0.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Equillium is working to fund operations through 2029. It is developing EQ504. The company has raised money from a private placement. It has beaten earnings twice recently.
Equillium is still losing money and has volatile management. It missed earnings in May 2026. The company has no revenue and negative cash flow. Its stock price is down 10% from the high.
The market prices the stock well below our fair value of $10.51. The Street median target is $6, much lower than our view.
Breaks if: Development of EQ504 stalls or funds are insufficient
Allocate resources to fund the development of EQ504 using proceeds from private placement.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent financial performance, but it operates in a sector that has favorable momentum.
The current valuation suggests that the market sees EQ as relatively cheap compared to its peers. However, there is a notable expectations gap, indicating that investors may be cautious about the company's ability to meet future performance targets.
Management has prioritized advancing clinical developments, but the execution has been mixed. The near-term risk is elevated due to the company's weak recent performance and the potential for further earnings misses in a high-miss-rate industry.
The long-term thesis hinges on management's ability to advance key clinical programs and maintain sufficient cash to fund operations. Additionally, the performance of sector bellwethers and the overall economic environment will be critical in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Cash falls below levels needed to fund operations into 2029
Ensure cash and cash equivalents are sufficient to fund currently planned operations into 2029.
Breaks if: Losses worsen or cash flow deteriorates further
Ensure cash and cash equivalents are sufficient to fund currently planned operations into 2029.
In the next 1 to 3 years, EQ's trajectory will depend on its clinical advancements and market conditions. Not investment advice.